# Study of Motexafin Gadolinium With Whole Brain Radiation Therapy Followed by Stereotactic Radiosurgery Boost in the Treatment of Patients With Brain Metastases

> **NCT00121420** · PHASE2 · TERMINATED · sponsor: **Pharmacyclics LLC.** · enrollment: 45 (—)

## Conditions studied

- Neoplasm Metastasis
- Brain Neoplasms

## Interventions

- **DRUG:** Motexafin gadolinium

## Key facts

- **NCT ID:** NCT00121420
- **Lead sponsor:** Pharmacyclics LLC.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** —
- **Primary completion:** —
- **Final completion:** —
- **Target enrollment:** 45 (—)
- **Last updated:** 2014-05-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00121420

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00121420, "Study of Motexafin Gadolinium With Whole Brain Radiation Therapy Followed by Stereotactic Radiosurgery Boost in the Treatment of Patients With Brain Metastases". Retrieved via AI Analytics 2026-09-09 from https://api.ai-analytics.org/clinical/NCT00121420. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*